The new SARCLISA J-code J9227 is now available, effective October 1, 2020, to be used for reimbursement claims. Refer to the Billing and Coding Guide on the Resources page for additional details. MAT-US-2018558-v1.0-08/2020

Superior PFS with SARCLISA + Pd vs Pd alone1

See the Full Efficacy Data

75-minute infusion time after the second infusion (in the absence of IRRs)1

View Dosing

Resources to help eligible patients access SARCLISA

Learn About CareASSIST

*ORR included sCR, CR, VGPR, and PR. sCR, CR, VGPR, and PR were evaluated by an IRC using the IMWG response criteria. CR=complete response; IMWG=International Myeloma Working Group; IRC=independent response committee; IRR=infusion-related reaction; ORR=overall response rate; PFS=progression-free survival; PR=partial response; sCR=stringent complete response; VGPR=very good partial response.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Category 1 recommendation for isatuximab-irfc (SARCLISA)

Isatuximab-irfc (SARCLISA) is the only mAb in combination with pomalidomide and dexamethasone included as an NCCN Guidelines® Category 1 recommended regimen for previously treated multiple myeloma.2

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

mAb=monoclonal antibody; NCCN=National Comprehensive Cancer Network.

Expert review Join Joseph Mikhael, MD, and Kenneth Shain, MD, PhD, as they discuss the clinical data for SARCLISA
Video icon
References: 1. SARCLISA [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.4.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed June 16, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org.